|
Press Releases |
|
|
|
Friday, October 30, 2020 |
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
Wednesday, October 28, 2020 |
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
Tuesday, September 22, 2020 |
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
Friday, September 4, 2020 |
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
Wednesday, July 22, 2020 |
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
Thursday, July 9, 2020 |
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
Tuesday, June 9, 2020 |
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
Thursday, April 9, 2020 |
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
Thursday, April 2, 2020 |
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
Friday, March 20, 2020 |
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
The USPA and U.S. Polo Assn. Celebrate 135th Anniversary with Global Sport and Fashion Events and Launch of "Born to Play"
Jan 30, 2025 20:00 HKT/SGT
|
|
|
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
|
|
|
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
|
|
|
MHI Thermal Systems Receives 2024 Agency for Natural Resources and Energy Commissioner's Award from ECCJ for TEJ35AM Electric-Driven Transport Refrigeration Unit Integrated with Isuzu's ELF EV
Jan 30, 2025 14:13 JST
|
|
|
Mitsubishi Shipbuilding Receives Order for an Offshore Patrol Vessel from the Indonesian Maritime Security Agency
Jan 30, 2025 12:35 JST
|
|
|
Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies
Jan 30, 2025 11:56 JST
|
|
|
Fourth Star Launches Immersive Media Streaming Platform
Jan 30, 2025 10:30 HKT/SGT
|
|
|
Suzuki, Daihatsu, and Toyota Decide on the Release Schedule for Mini-Commercial Van Electric Vehicles
Jan 30, 2025 10:56 JST
|
|
|
Supply Chain Specialists OMP Strengthen Leadership to Support Strategic Growth
Jan 30, 2025 09:48 HKT/SGT
|
|
|
A Quantum Leap into Uplisting: Spectral Capital and the Next Generation of Computing
Jan 29, 2025 22:47 JST
|
|
|
NEC combines video analysis technology with generative AI to generate advice for improving work quality
Jan 29, 2025 10:08 JST
|
|
|
The Now Corporation (OTC:NWPN), Utilizing Its Subsidiary Green Rain Solar Inc., Advances EV Infrastructure in Rochester, NY
Jan 28, 2025 21:00 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Strengthen Disaster Response by Conducting Joint Training for Shared Refueling Stations
Jan 28, 2025 17:39 JST
|
|
|
Darwinbox introduces Payroll in the Philippines, as a part of Multi-Country Payroll Expansion across SEA
Jan 28, 2025 12:00 HKT/SGT
|
|
|
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 28, 2025 9:46 JST
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|